Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q6FHJ7
UPID:
SFRP4_HUMAN
Alternative names:
Frizzled protein, human endometrium
Alternative UPACC:
Q6FHJ7; B4DYC1; O14877; Q05BG7; Q1ZYW2; Q4G124; Q6FHM0; Q6PD64
Background:
Secreted frizzled-related protein 4 (SFRP4), also known as Frizzled protein in human endometrium, plays a pivotal role in bone morphogenesis and uterine function. It modulates Wnt signaling, crucial for cell growth and differentiation. SFRP4's involvement in regulating phosphate uptake highlights its significance in mineral metabolism.
Therapeutic significance:
SFRP4's link to Pyle disease, characterized by bone fragility and deformity, underscores its therapeutic potential. Targeting SFRP4 could lead to innovative treatments for bone disorders, offering hope for patients with skeletal fragility.